Molecular Templates has been delisted from Nasdaq due to non-compliance with listing rules.

From GlobeNewswire: 2024-12-19 16:10:00

Molecular Templates, Inc. received notice of delisting from Nasdaq due to being labeled a “public shell” and non-compliance with listing rules, causing the suspension of trading on December 26, 2024. The company focuses on developing biologic therapeutics for cancer treatment using Engineered Toxin Bodies. Trading in their securities is cautioned as highly speculative and risky. Molecular Templates emphasizes the importance of exercising extreme caution with investments in their securities due to limited resources. Forward-looking statements in the press release highlight potential risks and uncertainties, urging vigilance when considering investments in the company.



Read more at GlobeNewswire: Molecular Templates Announces Notice of Delisting and